[HTML][HTML] Efficacy and safety of Mavacamten for symptomatic Hypertrophic cardiomyopathy–an updated Meta-Analysis of randomized controlled trials
I Ullah, ST Rehan, Z Khan, SH Shuja, MH Shuja… - IJC Heart & …, 2024 - Elsevier
Hypertrophic cardiomyopathy (HCM) is an autosomal dominant disorder with risk of sudden
cardiac death (SCD) in children and adolescents. Mavacamten, also referred to as MYK …
cardiac death (SCD) in children and adolescents. Mavacamten, also referred to as MYK …
Evaluating the efficacy and safety of mavacamten in hypertrophic cardiomyopathy: A systematic review and meta-analysis focusing on qualitative assessment …
Background Hypertrophic Cardiomyopathy (HCM) is a complex cardiac condition
characterized by hypercontractility of cardiac muscle leading to a dynamic obstruction of left …
characterized by hypercontractility of cardiac muscle leading to a dynamic obstruction of left …
Myosin-Catalyzed ATP Hydrolysis in the Presence of Disease-Causing Mutations: Mavacamten as a Way to Repair Mechanism
A Chakraborti, JC Tardiff… - The Journal of Physical …, 2024 - ACS Publications
Hypertrophic cardiomyopathy is one of the most common forms of genetic cardiomyopathy.
Mavacamten is a first-in-class myosin modulator that was identified via activity screening on …
Mavacamten is a first-in-class myosin modulator that was identified via activity screening on …
[HTML][HTML] A Systematic Review and Meta-analysis of Efficacy and Safety of Mavacamten for the Treatment of Hypertrophic Cardiomyopathy
L Zheng, X Gu, Y Chen, D Liu - Reviews in Cardiovascular …, 2024 - pmc.ncbi.nlm.nih.gov
Background: Hypertrophic cardiomyopathy (HCM) is a common hereditary cardiomyopathy.
Mavacamten, a first-in-class cardiac myosin inhibitor, is considered to be a specific drug for …
Mavacamten, a first-in-class cardiac myosin inhibitor, is considered to be a specific drug for …
Efficacy and safety of mavacamten for the treatment of hypertrophic cardiomyopathy: an updated systematic review and meta-analysis of randomized controlled trials
NE Almansouri, SAUN Bukhari… - Annals of Medicine …, 2024 - journals.lww.com
The efficacy and safety profile of mavacamten, a cardiac myosin inhibitor for the treatment of
hypertrophic cardiomyopathy (HCM) is not well-established, prompting the need for an …
hypertrophic cardiomyopathy (HCM) is not well-established, prompting the need for an …
A Tale of Two Myofilaments: Molecular Insights into Cardiac Muscle Function in Health and Disease
A Chakraborti - 2024 - repository.arizona.edu
Cardiac muscle function is critical for the heart to function properly but the complex
mechanism behind it is still not well understood, especially at the molecular level …
mechanism behind it is still not well understood, especially at the molecular level …